drug trial

A phase 1 clinical trial has begun in Turin, Italy, to test the safety of RG2833 in adults with Friedreich's ataxia

posted on March 15, 2012 - 11:00am
The biopharmaceutical company Repligen Corp., headquartered in Waltham, Mass., has launched a phase 1 clinical trial to test its experimental compound, RG2833, in adults with Friedreich's ataxia (FA). The trial is the first of a therapy specifically developed to treat the underlying molecular cause of FA. The phase 1 trial is being conducted at San Luigi Gonzaga University Hospital in Turin,...

Jacobus is inviting 30 selected individuals with Lambert-Eaton myasthenic syndrome to participate in a placebo-controlled trial of 3,4-DAP

posted on January 25, 2012 - 6:00am
Update (Oct.

A drug approved in Europe to treat Lambert-Eaton myasthenic syndrome is now being tested in the United States; clinical trial participants sought

posted on November 18, 2011 - 6:00am
BioMarin Pharmaceutical of Novato, Calif., is conducting a multicenter study of 3,4-diaminopyridine phosphate (3,4-DAP), also known as amifampridine phosphate, in adults with Lambert-Eaton myasthenic syndrome (LEMS). There are eight U.S. trial sites, with additional sites planned for France, Germany, Italy, Poland and Spain.